UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 25, 2019

Emmaus Life Sciences, Inc.
(Exact name of registrant as specified in its charter)

Delaware	001-35527	87-0419387
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA	90503
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (310) 214-0065

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.001 par value	EMMA	OTCQB
Common Stock Purchase Warrants	EMMAW	OTC Pink

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 8.01 Other Events.

On October 29, 2019, Emmaus Life Sciences, Inc. issued a press release announcing that it had entered into a stock purchase agreement dated as of October 25, 2019 with a Korean corporate investor to sell in a direct placement to the investor 800,000 shares of Emmaus common stock at a price of $3.00 per share. A copy of the press release is included as Exhibit 99.1 to this Current Report and incorporated herein by reference.

ITEM 9.01 Financial Statements and Exhibits

(d) *Exhibits*

See the accompanying Index to Exhibits, which information is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 29, 2019

Emmaus Life Sciences, Inc.

By: /s/ JOSEPH C. SHERWOOD III
Name: Joseph C. Sherwood III
Title: Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description
5.1	Opinion of Gibson, Dunn & Crutcher LLP.
99.1	October 29, 2019 press release of Emmaus Life Sciences, Inc.

Exhibit 5.1

GIBSON DUNN

Gibson, Dunn & Crutcher LLP

555 Mission Street
San Francisco, CA 94105-0921
Tel 415.393.8200
www.gibsondunn.com

October 25, 2019

Emmaus Life Sciences, Inc.
21250 Hawthorne Boulevard, Suite 800
Torrance, CA 90503

Re: *Emmaus Life Sciences, Inc. Registration Statement on Form S-3*

Ladies and Gentlemen:

We have acted as counsel to Emmaus Life Sciences, Inc., a Delaware corporation (the "Company"), in connection with the preparation of the prospectus supplement dated October 25, 2019, filed with the Securities and Exchange Commission (the "Commission") pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the "Securities Act"), which supplements the Registration Statement on Form S-3, file no. 333-223203 (the "Registration Statement") and the prospectus therein, in connection with the registration for offer and sale by the Company of 800,000 shares of the Company's Common Stock, par value $0.001 per share (the "Shares"), in connection with the Stock Purchase Agreement dated as of October 25, 2019 by and between the Company and the purchaser set forth therein (the "Purchase Agreement").

In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of such documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinion set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies.

Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued and sold in accordance with the Purchase Agreement, will be validly issued, fully paid and non-assessable.
We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption "Legal Matters" in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

Very truly yours,

/s/ Gibson Dunn & Crutcher LLP

Gibson Dunn & Crutcher LLP

Exhibit 99.1

Emmaus Life Sciences Announces Equity Investment from a Corporate Investor

-- Company Enters Into Common Stock Purchase Agreement with Vivozon, Inc. --

Torrance CA, October 29, 2019 - Emmaus Life Sciences, Inc. (OTCQB: EMMA) a leader in sickle cell disease treatment, today reported that Vivozon, Inc. has executed a stock purchase agreement for the purchase of 800,000 shares of Emmaus common stock at $3.00 per share for a total equity investment of $2.4 million. The equity investment by Vivozon was made pursuant to Emmaus' effective S-3 shelf registration statement on file with the Securities and Exchange Commission. The closing of the equity investment is expected to occur on or about October 31, 2019, subject to Korean regulatory approval. The net proceeds from the sale of shares will be used for working capital and general corporate purposes, which may include repayment of indebtedness.

"Emmaus and Vivozon share the same dedication and commitment to improving the lives of patients that can benefit from their therapies and we are delighted that Vivozon has decided to make an equity investment in Emmaus," said Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus.

"Vivozon is impressed with the progress Emmaus has made in the commercialization of Endari in the U.S. and its prospects in other international markets and their plans and trials studying the use of the same pharmaceutical grade L-glutamine oral powder used in Endari as a new therapy for treating patients with diverticulosis and diabetes," said Dr. Doo Lee, Ph.D., Chief Executive Officer and Head of Research & Development at Vivozon.

About Vivozon, Inc.
Based in Seoul, South Korea, Vivozon specializes in the discovery, development and commercialization of small molecule drugs for the treatment of patients with unmet CNS medical needs by applying the innovative approach to rapidly identify the lead compounds using its unique ex vivo/phenotypic screening technology. The company is focused on the development of the safe non-opioid-next-generation pain killer for patients suffering from post-operative, neuropathic, cancer and other causes of pain. Vivozon's lead drug candidate, VVZ-149, is currently in phase 3 clinical trials (U.S.) for the treatment of post-operative pain. Currently, two back-up programs of second and third generation of VVZ-149 are active with many hits and new lead molecules. For more information, visit: http://www.vivozon.com.

About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. For more information, please visit www.emmauslifesciences.com.

About Endari® (L-glutamine oral powder)
Indication - Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Important Safety Information - The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari at: www.ENDARIrx.com/PI.

About Sickle Cell Disease
Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to organ damage, stroke, pulmonary complications, skin ulceration, infection and a variety of other adverse outcomes. Sickle cell disease is a significant unmet medical need, affecting approximately one hundred thousand patients in the U.S. and millions worldwide, the majority of which are of African descent. An estimated 1-in-365 African American children are born with sickle cell disease.

Forward-looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the expected closing of the equity investment and possible future research and development of Emmaus' product candidates. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including the possibility that the closing of the equity investment is delayed, risks and uncertainties inherent in drug research and development and uncertainties related to the company's working capital and ability to carry on its existing operations and obtain needed financing and other factors previously disclosed in the company's reports filed with the Securities and Exchange Commission, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and the company assumes no duty to update them.

Company Contact:
Emmaus Life Sciences, Inc.
Joseph (Jay) C. Sherwood III
Chief Financial Officer
(310) 214-0065, Ext. 3005
jsherwood@emmauslifesciences.com

Investor Relations Contact:
LifeSci Advisors
Bruce Mackle
(929) 469-3859
bmackle@lifesciadvisors.com

Media Contacts:
Russo Partners
David Schull or Caroline Cunningham
(858) 717-2310
david.schull@russopartnersllc.com
caroline.cunningham@russopartnersllc.com